REVENUES FROM CONTRACTS WITH CUSTOMERS
|6 Months Ended|
Jun. 30, 2023
|REVENUES FROM CONTRACTS WITH CUSTOMERS|
|REVENUES FROM CONTRACTS WITH CUSTOMERS||
NOTE 16. REVENUES FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Net Revenues
The Company’s net product revenues are summarized as follows:
The above table includes the authorized generic product within the line items for Targadox®, Ximino® and Exelderm®.
For the three and six-month periods ended June 30, 2023 and 2022, there were no customers that accounted for more than 10% of the Company’s total gross product revenue.
At June 30, 2023, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 22.0% and 17.3%. At December 31, 2022, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 16.7% and 10.4%.
Other revenue reflects royalties on sales of Rapifort® Wipes 2.5% in Japan, from Maruho Co., LTD. (“Maruho”), the Company’s exclusive out-licensing partner in Japan. Other revenue for the six-month period ended June 30, 2022 also reflects a net $2.5 million milestone payment from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the net payment.
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef